BIOCON BIOLOGICS GLOBAL PLC

BALANCE SHEET AS AT MARCH 31, 2026

(All amounts in US Dollars Thousands, except share data and unless otherwise stated)

	Notes	March 31, 2026	March 31, 2025
ASSETS			
Non-current assets			
Financial assets			
(i) Loan and advances	4	-	7,92,328
Total non-current assets		**-**	**7,92,328**
Current assets			
Financial assets			
(i) Trade receivables	1	2,445	3,021
(ii) Cash and cash equivalents	2	183	84
(iii) Other financial assets	3	-	28,045
Total current assets		**2,628**	**31,150**
TOTAL		**2,628**	**8,23,478**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	5	134	134
Other equity	6	2,494	1,088
Total equity		**2,628**	**1,222**
Non-current liabilities			
Financial liabilities			
(i) Borrowings	8	-	7,83,465
Total non-current liabilities		**-**	**7,83,465**
Current liabilities			
Financial liabilities			
(i) Trade payables	7	-	13,000
(ii) Other financial liabilities	9	-	25,791
Total current liabilities		**-**	**38,791**
TOTAL		**2,628**	**8,23,478**

BIOCON BIOLOGICS GLOBAL PLC

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts in US Dollars Thousands, except share data and unless otherwise stated)

	Notes	Year ended March 31, 2026	Period ended March 31, 2025
Income			
Revenue from operations	10	43,020	43,881
Other income	11	36,470	30,039
Total revenue		**79,490**	**73,920**
Expenses			
Purchase of traded goods	12	42,109	43,021
Other expenses	13	47	60
Finance cost	14	35,449	29,388
Total expenses		**77,605**	**72,469**
Profit before tax		**1,885**	**1,451**
Tax expense			
Current tax		479	363
Tax expense		**479**	**363**
Profit for the year		**1,406**	**1,088**

BIOCON BIOLOGICS GLOBAL PLC
STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2026
(All amounts in US Dollars Thousands, except share data and unless otherwise stated)

		Year ended March 31, 2026	Period ended March 31, 2025
I	**Cash flows from operating activities**		
	Profit after tax	**1,406**	**1,088**
	Adjustments to reconcile profit before tax to net cash flows:		
	Interest expense	35,449	29,388
	Interest income	(36,473)	(30,047)
	Tax expense	479	363
	Operating profit before working capital changes	**861**	**792**
	Movements in working capital		
	(Increase) in trade receivables	576	(3,021)
	(Increase) in loans and advances and other assets	1	(1)
	(Increase) in other financial assets and liabilities	58,482	-
	Increase in trade payable, other liabilities and provisions	(15,324)	11,044
	Cash generated from / (used in) operations	**44,596**	**8,813**
	Direct taxes paid	-	-
	Net cash flow (used in) / generated from operating activities	**44,596**	**8,813**
II	**Cash flows from investing activities**		
	Loan advanced to Susidiary	-	(7,92,328)
	Transfer of Loan advanced to Susidiary	7,92,328	-
	Interest received	-	-
	Net cash flow (used in) / generated from investing activities	**7,92,328**	**(7,92,328)**
III	**Cash flows from financing activities**		
	Proceeds from Senior Secured Loan	-	7,83,465
	Transfer of Senior Secured Loan	(7,83,465)	-
	Interest paid	(53,360)	-
	Proceeds from issue of equity shares	-	134
	Net cash flow generated from / (used in) financing activities	**(8,36,825)**	**7,83,599**
IV	**Net increasein cash and cash equivalents (I + II + III)**	**99**	**84**
V	Cash and cash equivalents at the beginning of the year	84	-
VI	**Cash and cash equivalents at the end of the year (IV + V)**	**183**	**84**
	Reconciliation of cash and cash equivalents as per statement of cash flow		
	Cash and cash equivalents		
	Balances with banks - on current accounts	183	84
	Total cash and cash equivalents [refer note 2]	**183**	**84**

BIOCON BIOLOGICS GLOBAL PLC
Notes to financial statements for the year ended March 31, 2026
(All amounts in US Dollars Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
1. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
(a)Unsecured, considered good	2,445	3,021
(b) Unsecured - credit impaired	-	-
	2,445	3,021
Allowance for credit loss	-	-
	2,445	**3,021**
2. Cash and cash equivalents		
Balances with banks:		
On current accounts	183	84
	183	**84**
3. Other financial assets		
Current		
VAT Receivables	-	1
Interest Accrued on loan to related party	-	28,044
	-	**28,045**
4. Loan and advances		
Loans to related parties	-	7,92,328
	-	**7,92,328**
5. Share capital		
Authorised		
Issued, subscribed and fully paid-up		
100,000 Equity shares of GBP 1 each	134	134
Total issued, subscribed and fully paid-up share capital	**134**	**134**
6. Other equity		
Surplus in the statement of profit and loss		
Balance as per the last financial statements	1,088	-
Profit for the year	1,406	1,088
Net surplus in the statement of profit and loss	**2,494**	**1,088**
7. Trade payables	**-**	**13,000**
8. Borrowings		
Non-current borrowings		
Senior Secured Notes	-	7,83,465
	-	**7,83,465**
9. Other financial liabilities		
Interest accrued but not due	-	25,791
	-	**25,791**

(All amounts in US Dollars Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Period ended March 31, 2025
10. Revenue from operations		
Sale of Products		
Traded goods	43,880	43,021
Support service cross charge to Group Companies	(860)	860
	43,020	**43,881**
11. Other income		
Foreign exchange fluctuations, net	(3)	(8)
Interest income on loan	36,473	30,047
	36,470	**30,039**
12. Purchase of traded goods	42,109	43,021
	42,109	**43,021**
13. Other expenses		
Legal and professional fees	45	39
Miscellaneous expenses	2	1
Director's fees	-	20
	47	**60**
14. Finance cost		
Interest on Senior Secured Notes	35,449	29,388
	35,449	**29,388**